Efficacy of olaparib (ola) plus abiraterone (abi) vs placebo (pbo) plus abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14365/5005

Title:	Efficacy of olaparib (ola) plus abiraterone (abi) vs placebo (pbo) plus abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial
Authors:	Mehra, N. Clarke, N. W. Armstrong, A. J. Oya, M. Shore, N. D. Procopio, G. Guedes, J. D. C. Arslan, Çağatay
Publisher:	Elsevier
Abstract:	[No abstract available]
Description:	Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Barcelona, SPAIN
URI:	https://doi.org/10.1016/j.annonc.2023.09.2753 https://hdl.handle.net/20.500.14365/5005
ISSN:	0923-7534 1569-8041
Appears in Collections:	WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

CORE Recommender

1

checked on Nov 20, 2024

60

checked on Nov 18, 2024

Check